ENLV News & Events

Enlivex commented on the Rain Foundation's announcement of a $100M liquidity commitment to Rain's prediction markets protocol, which currently positions Rain as the third-largest prediction market protocol globally by Total Value Locked, alongside Polymarket and Kalshi. "We believe that Rain's positioning among the three largest prediction market platforms globally is a major step in Rain's quest to become a leading decentralized prediction market protocol, and a meaningful validation of our treasury strategy," said Shai Novik, executive chairman of Enlivex. "We further believe that the scale of capital deployment reflects strong conviction in the continued growth of Rain, and reinforces our confidence in the dual strategy we have built for Enlivex."

Enlivex announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis.

Enlivex Therapeutics files to sell 23.33M ordinary shares for holders

Enlivex announced that it has received Clinical Trial Application, CTA, approval by the Danish Medicines Agency, DKMA, for the Phase 2b trial of Allocetra, the Company's clinical-stage immunotherapy, for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, OA. The planned global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial, recently approved by the FDA, has been designed to evaluate the efficacy and safety of intra-articular injections of Allocetra in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, which is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. The clinical trial is designed to enroll patients from clinical centers in the United States, Denmark and Poland.